Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) and Prothrombin G20210A heterozygosity: Response to t-PA therapy

Acta Dermato-Venereologica

Volumn 90, Issue 1, 2010, Pages 91-92

  Antunes, Joana ^a   Filipe, Paulo ^a   André, Marisa ^a   Fraga, Ana ^a   Miltenyi, Gabriel ^b   Gomes, Manuel Marques ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; DEFLAZACORT; DIPYRIDAMOLE; ENOXAPARIN; ILOPROST; IMMUNOGLOBULIN; PENTOXIFYLLINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDNISOLONE; PROSTAGLANDIN E1; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ADD ON THERAPY; ADULT; ARM; CASE REPORT; COLD EXPOSURE; CYANOSIS; DRUG WITHDRAWAL; FEMALE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LABORATORY TEST; LEG; LETTER; LIVEDOID VASCULOPATHY; MULTIPLE CYCLE TREATMENT; NECROSIS; PRESCRIPTION; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DISCOLORATION; SKIN DISEASE; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ULCER; VASCULAR DISEASE;

EID: 76349110545     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0760     Document Type: Letter

References (15)

1. Hairston B, Davis D, Pittelkow M, Ahmed I. Livedoid Vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol 2006; 142: 1413-1418.
2. Acland K, Darvay A, Wakelin S, Russell-Jones R. Livedoid vasculitis: a manifestation of the antiphospholipid syndrome? Br J Dermatol 1999; 140: 131-135.
3. Boyvat A, Kundakci N, Babikir M, Gurgey E. Livedoid vasculopathy associated with heterozygous protein C deficiency. Br J Dermatol 2000; 143: 840-842.
4. Kavala M, Kocaturk E, Zindanci I, Turkoglu Z, Altintas S. A case of livedoid vasculopathy associated with factor V Leiden mutation: successful treatment with oral warfarin. J Dermatolog Treat 2008; 19: 121-123.
5. Gotlib J, Kohler S, Reicherter P, Oro AE, Zehnder JL. Heterozygous prothrombin G20210A gene mutation in a patient with livedoid vasculitis. Arch Dermatol 2003; 139: 1081-1083.
6. Browning C, Callen J. Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyper-homocysteinemia. Arch Dermatol 2006; 142: 75-78.
7. Deng A, Gocke CD, Hess J, Heyman M, Paltiel M, Gaspari A. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator. Arch Dermatol 2006; 142: 1466-1469.
8. Cardoso R, Gonçalo M, Tellechea O, Maia R, Borges C, Silva JA, Figueiredo A. Livedoid vasculopathy and hyper-coagulability in a patient with primary Sjögren syndrome. Int J Dermatol 2007; 46: 431-434.
9. Juan WH, Chan YS, Lee JC, Yang LC, Hong HS, Yang CH. Livedoid vasculopathy: long-term follow-up results following hyperbaric oxygen therapy. Br J Dermatol 2006; 154: 251-255.
10. Kreuter A, Gambichler T, Breuckmann F, Bechara FG, Rotterdam S, Stücker M, Altmeyer P. Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients. J Am Acad Dermatol 2004; 51: 574-579.
11. Zanini M, Wulkan C, Bertino D, Ito L. Livedoid vasculopathy or vasculitis? An Bras Dermatol 2003; 78: 755-757.
12. Kohler H, Grant P. Plasminogen-activator inhibitor type 1 and coronary heart disease. N Engl J Med 2000; 342: 1792-1801.
13. Martínez-Calatrava MJ, Martínez-Larrad MT, Zabena C, González-Sánchez JL, Fernández-Pérez C, Serrano-Ríos M. The 4G/4G PAI-1 genotype is associated with elevated plasma PAI-1 levels regardless of variables of the metabolic syndrome and smoking status. A population-based study in Spanish population. Diabetes Obes Metab 2007; 9: 134-135
14. Poort S, Rosendaal F, Reitsma P, Bertina R. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
15. Doggen C, Cats V, Bertina R, Rosendaal F. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998; 97: 1037-1041.